Neurology Licensing Deal Calculator —
benchmark your deal in 60 seconds
Phase 2 CNS deals median ~$50M upfront, ~$600M total. Rare CNS (e.g., DMD, SMA, ALS) commands a 2–3x premium on upfront. Built on 1,900+ verified biopharma transactions across 12 therapeutic areas.
Neurology deal benchmarks at a glance
Median deal terms for neurology licensing transactions, by development phase. Data current as of 2026.
| Phase | Median Upfront | Median Total Value | Median Royalty (Tiered) |
|---|---|---|---|
| Preclinical | $30M | $550M | 4–8% |
| Phase 1 | $45M | $800M | 6–12% |
| Phase 2 | $165M | $1.5B | 10–16% |
| Phase 3 | $275M | $2B | 13–20% |
Source: Ambrosia Benchmarker dataset, 1,900+ verified transactions (2017–2026). Primary sources: SEC EDGAR 8-K filings, FTC premerger notifications, ClinicalTrials.gov.
Recent comparable deals
- BMS–Karuna ($14B acquisition, KarXT)
- Sanofi–Novavax (acquired Novavax CNS pipeline)
- BioMarin–Aerpio
Why Neurology is priced this way
CNS programs have historically faced higher CRL rates and longer trials, depressing upfronts. The recent wave of GLP-1, anti-amyloid, and gene therapy approvals is shifting that dynamic.
Try it live
Run a Neurology deal scenario
Pick your phase, modality, and indication. Get instant benchmark ranges — no signup needed to start.
Quick Benchmark
Live data from 1,900+ deals. Select your parameters:
Neurology licensing — frequently asked
What is the median upfront payment for a Neurology licensing deal?
How are Neurology deal milestones structured?
What royalty rates are typical for Neurology licensing?
Is there a free Neurology deal calculator?
How does Neurology licensing compare to other therapeutic areas?
7-Day Free Trial · No Promo Code
Run unlimited neurology deals — Pro.
Monte Carlo sensitivity, partner matching across 850+ companies, scenario comparison (Bear/Base/Bull rNPV), and board-ready PDF reports. Free for 7 days. Cancel anytime.
Then $299/month · No charge during trial · Cancel anytime